P
Procarta Biosystems
Development of antibacterial therapy
About Procarta Biosystems
Procarta Biosystems is a pioneering biotech company focused on combating antimicrobial resistance (AMR), one of the most critical global healthcare threats today. The company specializes in the discovery and development of novel oligonucleotide antimicrobial agents designed to be effective against resistant bacterial strains. These agents feature a controllable microbiological spectrum, allowing for targeted treatment and minimizing the risk of resistance development. Procarta Biosystems operates in the pharmaceutical and biotechnology market, primarily serving healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potentially direct sales of their proprietary antimicrobial agents. The company's innovative approach and rapid, rational design process set it apart in the competitive landscape of antimicrobial drug development.
Source: Dealroom company dataAt a glance
- Founded
- 2007
- Headquarters
- London, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Iceni Seedcorn Fund
Morningside Venture Partners
CARB-X
Series A4 investors entered at this stage
Future Planet Capital
Wren Capital
Novo Holdings
Development Bank of Wales
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Procarta Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Procarta Biosystems on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.